GlassScriptPhysician profile
Tanika R Taylor
NPI 1396900445
$4,093.69
in general payments reported to CMS, 2019-2025
38 companies · $507 in 2025
The $507 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $443 · 2021: $719 · 2022: $710 · 2023: $763 · 2024: $346 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,616.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,049.66 | 2019-2024 | Lo Loestrin Fe, Liletta, Orilissa |
| Amgen INC. | $554.67 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $397.25 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $222.85 | 2020-2025 | Slynd |
| Mayne Pharma Commercial LLC | $184.06 | 2021-2025 | |
| Radius Health, INC. | $141.28 | 2019-2021 | |
| Penumbra, INC. | $130.12 | 2025 | Ruby Coil |
| Astellas Pharma US INC | $119.06 | 2023-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $112.11 | 2023-2024 | Aptima, Novasure, Acessa Provu System |
| Merck Sharp & Dohme LLC | $107.19 | 2020-2025 | Gardasil 9, Gardasil |
| Avion Pharmaceuticals | $99.63 | 2020-2023 | Balcoltra |
| Bayer Healthcare Pharmaceuticals INC. | $89.32 | 2020-2023 | |
| Pfizer INC. | $85.29 | 2022-2024 | |
| Agile Therapeutics, INC. | $81.02 | 2022-2023 | Twirla |
| Organon LLC | $73.18 | 2023-2025 | Nexplanon, Jada System |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $67.89 | 2022 | |
| Mylan Pharmaceuticals INC. | $64.00 | 2021-2022 | |
| Evofem Biosciences, INC. | $59.04 | 2021-2022 | |
| Therapeuticsmd, INC. | $55.22 | 2019-2022 | |
| Coopersurgical, INC. | $52.75 | 2019-2025 | Paragard T 380a |
| Biogen, INC. | $46.15 | 2025 | Zurzuvae |
| Allergan, INC. | $40.77 | 2019-2020 | |
| Duchesnay USA Incorporated | $31.66 | 2019 | |
| Novo Nordisk INC | $22.20 | 2025 | Wegovy |
| Virtus Pharmaceuticals LLC | $19.23 | 2021 | |
| Ascend Therapeutics US, LLC | $17.60 | 2020 | |
| Vertical Pharmaceuticals, LLC | $15.70 | 2019 | |
| Exact Sciences Corporation | $15.41 | 2025 | Cologuard Collection Kit |
| Baxter Healthcare | $15.21 | 2019 | |
| Scynexis, INC. | $15.08 | 2022 | |
| Smith+Nephew, INC. | $15.01 | 2025 | Pico 7, Pico 14 |
| Mycovia Pharmaceuticals, INC. | $14.81 | 2023 | Vivjoa |
| Millicent US INC | $14.46 | 2025 | Femlyv |
| Dermira, INC. | $14.16 | 2019 | |
| Zyla Life Sciences, INC. | $14.01 | 2020 | |
| Minerva Surgical, INC | $13.64 | 2022 | |
| Lupin INC. | $12.17 | 2019 | |
| Ferring Pharmaceuticals INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanika Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.